Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | RNase H family protein | 0.1081 | 0.2283 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0273 | 0.0283 | 0.6953 |
Echinococcus multilocularis | ribonuclease H1 | 0.1081 | 0.2283 | 1 |
Onchocerca volvulus | Ribonuclease H1 homolog | 0.1081 | 0.2283 | 1 |
Schistosoma mansoni | phosphoglucomutase | 0.1081 | 0.2283 | 0.2283 |
Treponema pallidum | ribonuclease H (rnhA) | 0.1081 | 0.2283 | 0.5 |
Loa Loa (eye worm) | plexin A | 0.0323 | 0.0407 | 1 |
Trypanosoma brucei | ingi protein (ORF1) | 0.1176 | 0.2519 | 0.0305 |
Wolbachia endosymbiont of Brugia malayi | ribonuclease HI | 0.1081 | 0.2283 | 0.5 |
Schistosoma mansoni | plexin | 0.0273 | 0.0283 | 0.0283 |
Schistosoma mansoni | phosphoglucomutase | 0.1081 | 0.2283 | 0.2283 |
Toxoplasma gondii | ribonuclease HI protein | 0.1081 | 0.2283 | 0.5 |
Brugia malayi | plexin A | 0.0323 | 0.0407 | 0.0619 |
Trypanosoma brucei | retrotransposon hot spot protein 4 (RHS4), interrupted | 0.1176 | 0.2519 | 0.0305 |
Trypanosoma brucei | RNA helicase, putative | 0.4196 | 1 | 1 |
Echinococcus granulosus | ribonuclease H1 | 0.1081 | 0.2283 | 1 |
Trypanosoma brucei | hypothetical protein, conserved | 0.1176 | 0.2519 | 0.0305 |
Trypanosoma brucei | ingi protein (ORF1) | 0.1176 | 0.2519 | 0.0305 |
Brugia malayi | RNase H family protein | 0.1081 | 0.2283 | 1 |
Trypanosoma brucei | unspecified product | 0.1176 | 0.2519 | 0.0305 |
Giardia lamblia | Ribonuclease H | 0.1081 | 0.2283 | 0.5 |
Brugia malayi | RNase H family protein | 0.1081 | 0.2283 | 1 |
Trypanosoma cruzi | ribonuclease H1, putative | 0.1081 | 0.2283 | 0.5 |
Trichomonas vaginalis | ribonuclease H1, putative | 0.1081 | 0.2283 | 0.5 |
Trypanosoma cruzi | ribonuclease H1, putative | 0.1081 | 0.2283 | 0.5 |
Schistosoma mansoni | phosphoglucomutase | 0.1081 | 0.2283 | 0.2283 |
Leishmania major | ribonuclease H1, putative | 0.1081 | 0.2283 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.